- TOP >
- Drug Discovery and Development
Drug Discovery and Development
The driving force for innovative drug creation revolutionizing the drug discovery process.
The mission of a R&D-driven pharmaceutical company is to continuously generate innovative pharmaceutical products. Daiichi Sankyo RD Novare has an advanced drug discovery platform built in-house, consisting of cutting-edge drug discovery technologies and high-quality clinical development. We aim to become the driving force behind drug discovery by building an innovative drug discovery process ahead of changes in drug discovery needs.
Accelerating R&D of New Drugs
Daiichi Sankyo RD Novare solves the bottlenecks faced by the pharmaceutical R&D stage through its advanced drug discovery platform. We are working in close cooperation with project members to quickly achieve the criteria required for each R & D stage. Daiichi Sankyo RD Novare's advanced expertise in each area is driving Daiichi Sankyo's drug discovery innovation and contributing to the establishment of a competitive advantage in the pharmaceutical industry.
Transforming the Drug Discovery Process.
We will reform our drug discovery process by further evolving our drug discovery platform. We will expand the application of our core technologies cultivated through small molecular drug discovery to new modalities, build a translational research foundation that enables drug discovery based on disease mechanisms, and build an information analysis foundation that handles large-scale data. We will introduce advanced processes to accelerate early development in the oncology field. We will also build a productive drug discovery ecosystem through active collaboration with medical institutions, academia and companies with groundbreaking new technologies.
Three R&D Units to Enhance the Productivity of Drug Discovery
Daiichi Sankyo RD Novare's business consists of three units: the Drug Discovery Research Unit, which is responsible for identifying compounds with the potential to be drugs, such as drug efficacy, kinetics, and safety; the Translational Research Unit, which aims to improve the probability of successful drug discovery through non-clinical and clinical research such as pathology, genomics, and bioinformatics; and the Clinical Development Unit, which is responsible for monitoring and data collection and analysis in conjunction with medical professionals at the clinical development stage. Cooperation of these units according to the stage of research and development enables the R&D of innovative new drugs that are not available in other pharmaceutical companies.
Evolving Drug Discovery Platforms
Daiichi Sankyo RD Novare has multiple drug discovery platforms that pursue the expertise of each unit, which consist of various "core technologies" developed by experts in each area. By effectively operating this Drug Discovery Platform, we will be able to significantly accelerate the drug discovery research and development process.
What is the Core Technologies?
Based on our in-house deepened core technologies, we have identified "core technologies" as technologies with competitive advantages that will be the key to gaining a unique position in the pharmaceutical industry. Individual core technologies are created through trial and error by internal experts and through collaboration and technological development through open innovation.
What is the Drug Discovery Platform?
To improve the productivity of the drug discovery process and to resolve issues flexibly according to challenges, we will combine related core technologies to build a "drug discovery platform." It is Daiichi Sankyo RD Novare's "Drug Discovery Platform" that continues to evolve by consolidating the enormous amount of data and know-how obtained from the R&D process.